SAM
CRNX

Silvercrest Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Silvercrest Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87M Sell
156,738
-6,895
-4% -$256K 0.04% 431
2026
Q1 		$5.94M Buy
163,633
+19,394
+13% +$866K 0.04% 401
2025
Q4 		$6.71M Buy
+144,239
New +$6.42M 0.05% 393

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silvercrest Asset Management's CRNX Position: Q2 2026 in Review

Silvercrest Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 4.2% in Q2 2026, selling an estimated $256K and leaving 156,738 shares worth $5.87M. The position accounts for 0.04% of the portfolio, ranked #431.

Silvercrest Asset Management first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.71M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Silvercrest Asset Management held 156,738 shares of Crinetics Pharmaceuticals worth $5.87M as of Q2 2026.
  • Silvercrest Asset Management sold 6,895 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $256K.
  • Crinetics Pharmaceuticals made up 0.04% of Silvercrest Asset Management's portfolio in Q2 2026, its #431 holding.
  • Silvercrest Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Silvercrest Asset Management's Crinetics Pharmaceuticals position peaked at $6.71M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.